Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pulmonary Disease, Chronic Obstructive: later-stage trial registry
7 of 75 indexed Pulmonary Disease, Chronic Obstructive trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #178 of 28,707 conditions by registered trial count.
75 US clinical trials · 7 currently recruiting · #178 of 28,707 conditions by registered trial count
Pulmonary Disease, Chronic Obstructive: 75 US clinical trials tracked, 7 recruiting.
Pulmonary Disease, Chronic Obstructive is the subject of 75 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 34 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 30 of these trials.
Enrollment posture brief
Registry condition pulmonary-disease-chronic-obstructive
OPEN 7 | RECR 9% | LATE 34 | EARLY 20 | RANK #178 | SPON 30
Volume-matched condition peers
Nearest open-share peer: Visual Acuity (10% recruiting · 21 trials)
Pulmonary Disease, Chronic Obstructive lists 7 open slots (9% of 75 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pulmonary Disease, Chronic Obstructive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pulmonary Disease, Chronic Obstructive is recruiting below its size-band peers.
7 of 75 indexed trials (9.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Pulmonary Disease, Chronic Obstructive research.
GlaxoSmithKline accounts for 30 of 75 trials (40%). 29 distinct sponsors appear on at least one study for this condition label.
-
Typical Pulmonary Disease, Chronic Obstructive enrolment sits around 295 participants.
Median target enrolment is 295 among the 75 trials that report a genuine target (sentinel values excluded). 22 of those (29.3%) plan for fewer than 100 participants.
-
Pulmonary Disease, Chronic Obstructive research is mostly interventional.
66 interventional and 9 observational studies make up this index (88% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
75 total, page 2 of 2
A Cognitive-Behavioral Intervention for Depression and Anxiety in COPD
US Department of Veterans Affairs
NCT00105911
Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
GlaxoSmithKline
NCT00355342
Outlook: An Intervention to Improve Quality of Life in Serious Illness
Duke University
NCT00939146
A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD
Abgenix
NCT00035828
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD
Boehringer Ingelheim
NCT00239447
Problem-Solving Therapy for People With Major Depression and Chronic Obstructive Pulmonary Disease
Weill Medical College of Cornell University
NCT00601055
A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
Centocor
NCT00380796
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
Boehringer Ingelheim
NCT01662986
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
GlaxoSmithKline
NCT00749411
Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses
GlaxoSmithKline
NCT01894386
Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Brigham and Women's Hospital
NCT00595114
Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
University of Michigan
NCT00281242
Peripheral Nerve Blocks for Above-the-knee Amputations
University of Florida
NCT03404180
A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects
GlaxoSmithKline
NCT02006537
Transforming Psychotherapy for Chronically Ill Patients
US Department of Veterans Affairs
NCT00520429
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
University of North Carolina, Chapel Hill
NCT02464059
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects
GlaxoSmithKline
NCT02691325
Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD
VA Greater Los Angeles Healthcare System
NCT03370835
The Trajectory of Physical Activity Following Pulmonary Rehabilitation
Trinity Health Of New England
NCT02399254
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib
GlaxoSmithKline
NCT03398421
Real-Time Support for Exercise Persistence in COPD
University of Washington
NCT00373932
Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest
Johns Hopkins University
NCT04170062
Abdominal Functional Electrical Stimulation to Reduce Hyperinflation in Chronic Obstructive Pulmonary Disease Patients
Liberate Medical
NCT02035228
Home COPD and Open Ventilation Evaluation (HOPE) Study
Landon Pediatric Foundation
NCT03691181
Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD
Boehringer Ingelheim
NCT04795323
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 13 |
| Phase 3 | 22 |
| Phase 4 | 12 |
Top Sponsors
Named interventions
Most-linked intervention names on Pulmonary Disease, Chronic Obstructive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pulmonary Disease, Chronic Obstructive trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pulmonary Disease, Chronic Obstructive page
75 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Pulmonary Disease, Chronic Obstructive trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- GlaxoSmithKline sponsors the most Pulmonary Disease, Chronic Obstructive trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pulmonary Disease, Chronic Obstructive condition card totals 75 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.